Remodeling DNA to defeat disease
Foghorn Therapeutics (foghorntx.com) scores 55 out of 100 on Brand Analyzer, placing it in the Early Stage tier among Healthcare brands, in the 3rd percentile of 14000 Healthcare brands.
Foghorn Therapeutics is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2016. It develops precision therapeutic candidates that target the chromatin regulatory system, aiming to correct gene expression abnormalities implicated in cancer and other diseases. The company's approach focuses on remodeling the three-dimensional structure of DNA to address disease at its genetic source, positioning itself within the chromatin biology field for biopharmaceutical researchers, clinicians, and investors interested in novel cancer treatments.
| Brand Name | Foghorn Therapeutics |
|---|---|
| Domain | foghorntx.com |
| Industry | Healthcare |
| Founded | 2016 |
| Headquarters | Cambridge, United States |
| Main Competitors | Epizyme, Constellation Pharmaceuticals, Syros Pharmaceuticals, C4 Therapeutics (73/100), SpringWorks Therapeutics |
Moz Domain Authority 38/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #2,392,570 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Our precision therapeutic candidates remodel the shape of DNA to tackle disease." (Meta description: 12 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on X (Twitter), Instagram; no detected presence on LinkedIn, Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Foghorn Therapeutics?", Claude could identify the brand as of October 2026. Foghorn Therapeutics is a clinical-stage biopharmaceutical company that focuses on discovering and developing medicines targeting chromatin regulation, using their proprietary 'Gene Traffic Control' platform to understand and correct abnormal gene expression in cancer and other d Best known for Pioneering chromatin regulation-based drug discovery through its Gene Traffic Control platform to target cancers driven by epigenetic dysregulation.
When asked "Best brands similar to Foghorn Therapeutics?", Claude would recommend Foghorn Therapeutics as of October 2026. It's a notable and distinctive player in the chromatin/epigenetics biotech space, so I'd mention it if someone asked about innovative cancer biotech companies with unique platform technologies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Foghorn Therapeutics has limited AI-search visibility, scoring 29/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 22, recommendation 51). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Foghorn Therapeutics official site
Foghorn Therapeutics was founded in 2016. Foghorn Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Foghorn Therapeutics scores 51/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Foghorn Therapeutics official site
Foghorn Therapeutics is a biopharmaceutical company based in Cambridge, United States, founded in 2016. It focuses on developing precision therapeutics that target the chromatin regulatory system to treat cancer and other diseases rooted in gene expression abnormalities.
Sources: Foghorn Therapeutics official site
Foghorn Therapeutics develops precision therapeutic candidates designed to remodel the three-dimensional structure of DNA by targeting the chromatin regulatory system. This approach aims to correct breakdowns in gene expression that are implicated in more than half of all cancers, as well as other genetic diseases.
Sources: Foghorn Therapeutics official site
Foghorn Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Foghorn Therapeutics official site
Foghorn Therapeutics is known for pioneering a class of medicines that target the chromatin regulatory system, a novel approach in oncology that addresses gene expression abnormalities at their genetic source rather than through traditional cancer treatment mechanisms.
Sources: Foghorn Therapeutics official site
Foghorn Therapeutics' work is relevant to biopharmaceutical researchers, clinicians, patients, and investors who are focused on novel treatments for cancer and other genetic diseases rooted in chromatin and gene expression abnormalities.
Sources: Foghorn Therapeutics official site
Foghorn Therapeutics scores 29/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Foghorn Therapeutics has a weak AI-visibility profile at 29/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (51/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #2,392,570 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 38/100 and thin schema.org structured data. In a live check, Claude could already identify Foghorn Therapeutics from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Foghorn Therapeutics: Fluxion Bio (55/100), Exscribe (55/100), Functional Pathways (55/100), Ganot Capital (55/100).
A step up - brands to learn from: Word of Mouth Technology (56/100), Werskincare (56/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.